Volume | 547,134 |
|
|||||
News | - | ||||||
Day High | 39.02 | Low High |
|||||
Day Low | 38.44 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
38.46 | 38.44 | 39.02 | 38.57 | 38.46 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,662 | 547,134 | $ 38.67 | $ 21,159,581 | - | 29.85 - 45.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:49:43 | 50 | $ 37.13 | USD |
Halozyme Therapeutics Incorporated Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.89B | 126.82M | - | 829.25M | 281.59M | 2.22 | 17.37 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Halozyme Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 37.73 | 39.70 | 37.73 | 38.75 | 731,176 | 1.15 | 3.05% |
1 Month | 40.68 | 41.60 | 37.73 | 39.40 | 882,114 | -1.80 | -4.42% |
3 Months | 33.80 | 42.64 | 33.15 | 39.02 | 1,021,827 | 5.08 | 15.03% |
6 Months | 33.56 | 42.82 | 32.95 | 37.64 | 1,168,419 | 5.32 | 15.85% |
1 Year | 33.31 | 45.00 | 29.85 | 37.49 | 1,091,135 | 5.57 | 16.72% |
3 Years | 50.70 | 59.46 | 29.85 | 41.14 | 1,099,841 | -11.82 | -23.31% |
5 Years | 16.18 | 59.46 | 12.71 | 34.78 | 1,197,770 | 22.70 | 140.30% |
Halozyme Therapeutics Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |